I consent to InflaRx GmbH (Winzerlaer Str. 2, 07745 Jena, Germany) evaluating the personal data I have provided in the questionnaire regarding my health in order to determine whether I am a potential study participant for the clinical trial on the efficacy and safety of vilobelimab (IFX-1) in the treatment of ulcerative pyoderma gangrenosum (“PG”). If I am still eligible as a study participant after evaluation of the questionnaire, I also consent to my contact details and the health data contained in the questionnaire will be transmitted to the study center selected by me. The study site will contact me accordingly in order to coordinate the next steps. My consent is voluntary and can be withdrawn at any time with effect for the future.
Further details on data processing can be found in the privacy policy.
